# Prospective phase II trial of prognostication by ^{68}Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR targeted therapy

Supplemental Figure 1:

A: Arrow pointing to bronchopulmonary NET shown in Fig 1A. Tumor SUV$_{max}$: 3.2. Normal liver SUV$_{mean}$: 1.24. B: Arrow pointing to SI NET orbital metastasis shown in Fig 1B. Tumor SUV$_{max}$: 5.8. Normal liver SUV$_{mean}$: 1.42. C: Arrow pointing to pancreatic NET liver metastasis in Fig 1C. Tumor SUV$_{max}$: 6.8. Normal liver SUV$_{mean}$: 1.1. D: Arrow pointing to colon NEC intramuscular metastasis in Fig 1D. Tumor SUV$_{max}$: 3.5. Normal liver SUV$_{mean}$: 1.1

Supplemental Figure 2:

Cutoff Finder output depicting hazard ratio and 95% confidence interval (HR with 95% CI) when uPAR TLR is dichotomized at any possible cutpoint (x-axis). Solid vertical line is placed at median uPAR TLR (2.47).